Study to Evaluate Drug-Drug Interaction Between IDX719 and Simeprevir in Healthy Participants (MK-1894-004)

Inclusion Criteria: * Has no clinically significant abnormalities on medical history, physical examination, or 12-lead electrocardiogram (ECG) * Agrees to use a double method of birth control (one of which must be a barrier) from Screening through at least 90 days after the last dose of study drug * Agrees to avoid nicotine-containing products from 3 months prior to Screening and for the duration of the study Exclusion Criteria: * Is positive for hepatitis B surface antigen (HBsAg), anti-hepatitis C virus (HCV) antibodies, or anti-human immunodeficiency virus (HIV) antibodies * Is pregnant or breastfeeding * Has previously received either IDX719 or simeprevir * Has participated in another clinical drug study within 30 days of Screening